Oncotarget

Research Papers:

Combined gemcitabine and S-1 chemotherapy for treating unresectable hilar cholangiocarcinoma: a randomized open-label clinical trial

Hao Li, Zheng-Yun Zhang, Zun-Qiang Zhou, Jiao Guan, Da-Nian Tong and Guang-Wen Zhou _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2016; 7:26888-26897. https://doi.org/10.18632/oncotarget.8590

Metrics: PDF 1884 views  |   HTML 2561 views  |   ?  


Abstract

Hao Li1,2,*, Zheng-Yun Zhang2,*, Zun-Qiang Zhou2, Jiao Guan2, Da-Nian Tong2, Guang-Wen Zhou2

1Department of Surgery, Shanghai Jiao Tong University Affiliated First People’s Hospital, Shanghai, 200080, China

2Department of Surgery, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, 200233, China

*These authors have contributed equally to this work

Correspondence to:

Guang-Wen Zhou, email: [email protected]

Keywords: gemcitabine, S-1, hilar cholangiocarcinoma, chemotherapy, CA19-9

Received: November 02, 2015    Accepted: March 11, 2016    Published: April 5, 2016

ABSTRACT

Although the combination of cisplatin and gemcitabine (GEM) is considered the standard first-line chemotherapy against unresectable hilar cholangiocarcinoma (HC), its efficacy is discouraging. The present randomized open-label clinical trial aimed to evaluate the efficacy and safety of the GEM plus S-1 (GEM-S-1) combination against unresectable HC. Twenty-five patients per group were randomly assigned to receive GEM, S-1 or GEM-S-1. Neutropenia (56%) and leukopenia (40%) were the most common chemotherapy-related toxicities in the GEM-S-1 group. Median overall survival (OS) in the GEM-S-1, GEM and S-1 groups was 11, 10 and 6 months, respectively. GEM plus S-1 significantly improved OS compared to S-1 monotherapy (OR=0.68; 95%CI, 0.50–0.90; P=0.008). Median progression-free survival (PFS) times in the GEM-S-1, GEM and S-1 groups were 4.90, 3.70 and 1.60 months, respectively. GEM plus S-1 significantly improved PFS compared to S-1 monotherapy (OR=0.50; 95%CI, 0.27–0.91; P=0.024). Response rates were 36%, 24% and 8% in the GEM-S-1, GEM and S-1 groups, respectively. A statistically significant difference was found in response rates between the gemcitabine-S-1 and S-1 groups (36% vs 8%, P=0.017). Patients with CA19-9<466 U/ml were more responsive to chemotherapeutic agents than those with CA19-9≥571 U/ml (88.9% vs 0%, P<0.001). We conclude that the combination of GEM plus S-1 provides a better OS, PFS and response rate than S-1 monotherapy, but it did not significantly differ from GEM monotherapy. (ChiCTR-TRC-14004733).


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 8590